“Four years of remission with fulvestrant monotherapy in advanced endometrioid adenocarcinoma of the endometrium Harboring an ESR1 Mutation: A case Report”
•Progestin therapy is the preferred hormonal treatment for advanced endometrioid carcinoma.•Next-generation sequencing can aid decision-making in advanced disease.•ESR1 and CTNNB1 mutations are poor molecular prognostic factors.•Fulvestrant may be an option to treat patients with ESR1 mutations.
Authors
- Fabio Payão Pereira
- Mariana Carvalho Gouveia (ORCID: https://orcid.org/0000-0001-8194-7594)
- Mariana Scaranti (ORCID: https://orcid.org/0000-0001-7713-0100)
- Karoline Simões Baldotto Duarte
- Romulo Loss Mattedi (ORCID: https://orcid.org/0000-0001-6071-3000)
- Jennifer Feldmann
- João Henrique Lima Feldmann
Institutions
- Universidade Nove de Julho (BR)
- Instituto do Câncer do Estado de São Paulo (BR)
- Hospital Sírio-Libanês (BR)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1016/j.gore.2025.101752
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00